If Merck is running it they're just trying to show
Post# of 148101
(Total Views: 562)
Posted On: 05/19/2024 3:37:56 PM
Quote:
If Merck is running it they're just trying to show that together you see a better result, and boom!Quote:
With leronlimab downregulating PD-L1 and in return downregulating PD-1 any positives from Keytruda would be negligible. But with Keytruda you do have the added benefit of potential for acute kidney injury.
Quote:
They've got new life and we've got the exciting new darling of the oncology world.
Using both Keytruda and leronlimab together would not be a drug conjugate so it wouldn't be considered a new drug by the FDA or a patentable new drug. So Keytruda would still be standing on it's soon to expire original patent. It is possible they could conjugate the drugs considering they're both monoclonal antibodies. But that would add nothing of value to leronlimab's effectiveness. Much better to buy out Cytodyn, get leronlimab approved and leave Keytruda in the dustbin.
(13)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼